Metabolic and Morphologic Complications of HIV and HAART


•	Synthetic derivative of progesterone
•	Evaluated in two trials in patients with significant weight loss (>10%) and anorexia^{1, 2}
•	12-week duration
•	800 mg/day dose used
•	Measurements included weight, body composition, and caloric intake

1. Oster MH et al. Ann Intern Med. 1994;121:400-8. 2. Von Roenn JH. Ann Intern Med. 1994;121:393-9.

• Megestrol acetate has been evaluated in two randomized, double-blind, placebo-controlled trials.1, 2

• Patients who participated in these two studies had weight loss of 10% or more of their ideal body weight and anorexia.

• During the 12-week duration of each trial, patients were randomly assigned to placebo or megestrol acetate, given at a dose of 800 mg/day in a liquid, oral suspension formulation.

• Measurements taken at baseline, and again at various intervals, included weight, body composition, and caloric intake.

References:

1. Oster MH, Enders SR, Samuels SJ et al. Megestrol acetate in patients with AIDS and cachexia. Ann Intern Med. 1994;121:400-8.

2. Von Roenn JH, Armstrong D, Kotler DP et al. Megestrol acetate in patients with AIDS-related cachexia. Ann Intern Med. 1994;121:393-9.